Hydrocephalus Shunt Market – Product (Valves [Adjustable, Fixed], Catheters), Procedure (Ventriculoperitoneal, Lumboperitoneal, Ventriculoatrial, Ventriculopleural), Age Group (Pediatric, Adult), End Use (Hospitals, ASCs), Global Forecast (2024 – 2032)

Hydrocephalus Shunt Market – Product (Valves [Adjustable, Fixed], Catheters), Procedure (Ventriculoperitoneal, Lumboperitoneal, Ventriculoatrial, Ventriculopleural), Age Group (Pediatric, Adult), End Use (Hospitals, ASCs), Global Forecast (2024 – 2032)

Hydrocephalus shunt Market Size

Hydrocephalus Shunt Market size was valued at USD 460.5 Million in 2023 and is anticipated to showcase growth at 3.5% CAGR from 2024 – 2032. Increasing prevalence of congenital hydrocephalus, growing awareness towards surgical treatment of hydrocephalus, and availability of reimbursement coverage for hydrocephalus treatments is driving the growth in the hydrocephalus shunts market. Moreover, increasing geriatric population that is significantly prone to hydrocephalus is also driving the demand for hydrocephalus shunts globally.

To get key market trends

  Download Free Sample

A hydrocephalus shunt is a device utilized in managing hydrocephalus, a condition marked by the buildup of cerebrospinal fluid (CSF) in the brain's ventricles. This system comprises various parts intended to divert surplus CSF away from the brain to a different area of the body for natural absorption and processing. The condition is more prevalent among pediatric and geriatric population.
 

What are the growth opportunities in this market?

 Download Free Sample

Hydrocephalus Shunt Market Trends

• Ongoing advancements in shunt technology, including the development of programmable and adjustable shunts, are contributing to the adoption of complex hydrocephalus shunt surgeries. Advanced adjustable shunt technologies, like the Strata II (Medtronic plc) and M.blue valves (B. Braun Melsungen AG), are offering enhanced longevity, compatibility with MRI scans, and simplified adjustment procedures, eliminating the necessity for X-ray validation.
• Vendors are giving priority to the advancement of advanced sensor systems capable of precisely detecting and controlling variations in CSF drainage to tailor drainage according to individual requirements. Additionally, there is an increasing emphasis among vendors on the creation of improved biocompatible materials to reduce the likelihood of shunt infections.
• Recent advancements in various MRI systems and technologies including sagittal and coronal MRI, time-spatial labeling inversion pulse MRI, and phase-contrast MRI have demonstrated promising applicability in the diagnosis of normal pressure hydrocephalus, enabling early diagnosis and timely treatment using hydrocephalus shunting procedures.

Hydrocephalus shunt Market Analysis

Learn more about the key segments shaping this market

 Download Free Sample

Based on product, the market is segmented into hydrocephalus valves and hydrocephalus catheters. The hydrocephalus valves segment held the majority of market share in 2023 and is anticipated to grow at CAGR of 3.6% over the coming years.

• The majority share of the hydrocephalus valves segment can be attributed to high adoption of adjustable valves as they allow neurosurgeons to customize CSF drainage as per the requirement of individual patients thereby reducing the risk of over drainage-related complications.
• Advanced hydrocephalus valves are utilizing cutting-edge technology, including programmable settings and pressure-sensitive mechanisms to enhance their performance. These advanced features have allowed for continuous monitoring and adjustment of cerebrospinal fluid drainage, ultimately enhancing treatment effectiveness and patient outcomes, which is driving the adoption of valves in the market.

Learn more about the key segments shaping this market

 Download Free Sample

Based on procedure type, the hydrocephalus shunt market is classified into ventriculoperitoneal, lumboperitoneal, ventriculoatrial, and ventriculopleural. The ventriculoperitoneal segment dominated the market with a revenue of about USD 401.6 million in 2023.

• Preference of ventriculoperitoneal shunting procedure due to their higher reliability specifically during the treatment of congenital hydrocephalus, acquired hydrocephalus (such as post-hemorrhagic hydrocephalus), and normal pressure hydrocephalus is driving their adoption in market.
• Moreover, ventriculoperitoneal shunting procedures are less invasive than other procedures, resulting in reduced hospital stay and faster recovery time. As a result, it is preferred by patients and medical practitioners.
• Ventriculoperitoneal shunting procedures offers reduced risk of revisions in comparison to other surgical procedures, that enhances the long-term effectiveness and durability of ventriculoperitoneal shunting.

Based on age group, the hydrocephalus shunt market is classified into pediatric and adult. The pediatric segment secured a share of about 68.7% in 2023 and is anticipated to grow at 3.5% CAGR during the forecast period.

• High incidence of congenital hydrocephalus is driving the adoption of hydrocephalus shunt among pediatric patients. Pediatric patients born with congenital hydrocephalus often require prompt intervention, including shunt placement, to manage the condition and prevent neurological damage.
• Moreover, pediatric patients require hydrocephalus shunt placement in the early stage of their life, and ongoing management continues throughout childhood and adolescence. Due to longer treatment duration, multiple number of shunt procedures are performed in pediatric patients, contributing to the dominating share of the segment.

Based on end-use, the hydrocephalus shunt market is classified into hospitals and ambulatory surgery centers (ASCs). The hospital segment secured a share of about 71.5% in 2023 and is anticipated to grow at 3.2% CAGR during the forecast period.

• Hydrocephalus shunt procedures are typically performed as an inpatient procedure, that are preferably carried out in hospitals. Moreover, hospitals also provide outpatient services such as post-operative follow-up, shunt adjustments, and patient monitoring, which contributes to the dominating share of the hospitals segment.
• Additionally, hospitals function as centralized healthcare facilities with specialized infrastructure, operating rooms, and medical professionals capable of diagnosing and effectively treating hydrocephalus. Patients diagnosed with hydrocephalus usually undergo initial diagnosis, surgical procedures, postoperative care, and follow-up services across hospitals, contributing to the revenue growth of the segment

Looking for region specific data?

 Download Free Sample

North America hydrocephalus shunt market accounted for 40.2% of market share in global market in 2023 and is predicted to reach USD 238.7 million by 2032.

• Availability of a sophisticated healthcare infrastructure that includes state-of-the-art hospitals, specialized neurosurgical centers, and access to cutting-edge medical technology in the region is driving the demand for hydrocephalus shunting procedures.  
• Moreover, growing awareness towards hydrocephalus shunting procedures through awareness campaigns run by healthcare providers, hospitals, and patient advocacy groups such as the Hydrocephalus Association in the United States and the Hydrocephalus Canada Association, is driving the demand for timely treatment of hydrocephalus, thereby contributing to the revenue growth in North America.

The U.S. hydrocephalus shunt market was valued at USD 161.4 million in 2023 and is anticipated to grow at a CAGR of 3.1% over the forecast period.

• Increase in healthcare expenditure related to the treatment of hydrocephalus has led the healthcare settings to adopt proactive treatment approach, thereby driving an increase in early diagnosis and surgical treatments.
• Availability of reimbursement and coverage for hydrocephalus shunting procedures in the U.S. is also driving the patients to opt for elective surgical treatments.
• Increasing investments in research and development from vendors have led to an increased availability of advanced hydrocephalus shunt products in the country. For instance, according to the ClinicalTrials.gov, as of April 2024, about 77 clinical trial studies were active in the U.S.
• Moreover, presence of established healthcare infrastructure together with large number of established vendors in U.S. offering advanced products is contributing towards increasing adoption of hydrocephalus valves and catheters in the country, thereby driving the revenue growth in the market.

Germany hydrocephalus shunt market is expected to show significant growth during the forecast period.

• With the aging population, the incidence of conditions like normal pressure hydrocephalus (NPH) is increasing in Germany. According to The World Bank statistics, population aged 65 and above in Germany increased from 20% of total population in 2012 to 22% in 2022. As a result, the demand for surgical intervention such as hydrocephalus shunting has increased in the country, fueling the market growth.
• Germany’s well developed health system supported by the presence of skilled neurosurgeons, neurologists, and multidisciplinary teams specializing in the diagnosis and treatment of hydrocephalus is further contributing to the increasing number of hydrocephalus shunting procedures, contributing to the market growth.

India hydrocephalus shunt market is anticipated to grow remarkably over the coming years.

• Growing investments in India to upgrade its existing healthcare infrastructure, including the expansion of hospitals, neurosurgical centers, and clinics, well equipped to diagnose and treat hydrocephalus, has surged the patient’s accessibility to advanced treatment options for hydrocephalus.
• Moreover, rise in healthcare financing, such as health insurance plans and government-backed healthcare initiatives, have made hydrocephalus treatments more cost-effective and within reach for patients in India. This increased affordability and accessibility are encouraging more individuals to promptly seek timely treatment for hydrocephalus.

Hydrocephalus Shunt Market Share

The hydrocephalus shunt industry is highly fragmented due to the presence of large number of established vendors and new entrants. Advancements in materials science, miniaturization, and manufacturing processes have made it more viable for smaller companies to develop and produce hydrocephalus shunt devices. Established vendors are adopting collaborations and partnership as a key strategy to gain competitive edge in the market. Small scale vendors are relying towards offering low-cost products to compete with established players in the market.

Hydrocephalus Shunt Market Companies

Prominent players operating in the hydrocephalus shunt industry include

• B. Braun Melsungen AG
• CHRISTOPH MIETHKE GMBH & CO. KG
• DESU MED?KAL A.?.
• G. Surgiwear Ltd.
• Hpbio
• Integra LifeSciences Corporation
• Kaneka Medix Corp.
• Luciole Medical AG
• Medtronic plc
• Natus Medical Incorporated
• SOPHYSA
• TKB Corporation   

Hydrocephalus Shunt Industry News

• In June 2023, Luciole Medical AG announced the acquisition of Spiegelberg GmbH & Co. KG, a specialized medical device company offering hydrocephalus shunting products. The Luciole Medical AG aimed to combine its product suites, manufacturing, and distribution channels, to optimize its strengths to become a global leader in innovative brain monitoring devices.
• In May 2020, Aesculap, Inc., a subsidiary of B. Braun Melsungen AG in partnership with Christoph Miethke GmbH & Co. KG, jointly announced to launch M.blue valve, the latest generation of Hydrocephalus valve technology.

The hydrocephalus shunt market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments

Click here to Buy Section of this Report

Market, By Product type

• Hydrocephalus valves
  • Adjustable pressure valves
  • Fixed pressure valves
• Hydrocephalus catheters
  • Standard catheters
  • Antimicrobial catheters

Market, By Procedure type

• Ventriculoperitoneal
• Lumboperitoneal
• Ventriculoatrial
• Ventriculopleural

Market, By Age group

• Pediatric
• Adult

Market, By End-use

• Hospitals
• Ambulatory surgery centers

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa